D.A. Davidson & CO. cut its stake in shares of UiPath, Inc. (NYSE:PATH - Free Report) by 22.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 585,698 shares of the company's stock after selling 166,750 shares during the period. D.A. Davidson & CO. owned approximately 0.11% of UiPath worth $9,600,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Sumitomo Mitsui Trust Group Inc. raised its position in shares of UiPath by 1.9% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 37,871 shares of the company's stock worth $621,000 after purchasing an additional 720 shares during the period. Green Alpha Advisors LLC raised its position in shares of UiPath by 3.4% during the fourth quarter. Green Alpha Advisors LLC now owns 29,519 shares of the company's stock worth $484,000 after purchasing an additional 973 shares during the period. Covestor Ltd raised its position in shares of UiPath by 17.7% during the third quarter. Covestor Ltd now owns 6,522 shares of the company's stock worth $87,000 after purchasing an additional 981 shares during the period. Wealthfront Advisers LLC raised its position in shares of UiPath by 3.6% during the third quarter. Wealthfront Advisers LLC now owns 32,886 shares of the company's stock worth $440,000 after purchasing an additional 1,149 shares during the period. Finally, CoreCap Advisors LLC raised its position in shares of UiPath by 92.3% during the fourth quarter. CoreCap Advisors LLC now owns 2,579 shares of the company's stock worth $42,000 after purchasing an additional 1,238 shares during the period. 62.50% of the stock is owned by institutional investors and hedge funds.
UiPath Trading Up 1.0%
NYSE:PATH opened at $10.56 on Wednesday. The firm has a market capitalization of $5.53 billion, a price-to-earnings ratio of 20.31, a PEG ratio of 1.71 and a beta of 1.03. UiPath, Inc. has a 1-year low of $9.28 and a 1-year high of $19.84. The business's fifty day moving average price is $10.98 and its 200 day moving average price is $13.64.
UiPath (NYSE:PATH - Get Free Report) last issued its earnings results on Wednesday, March 11th. The company reported $0.30 EPS for the quarter, beating analysts' consensus estimates of $0.25 by $0.05. UiPath had a return on equity of 5.69% and a net margin of 17.53%.The firm had revenue of $481.11 million for the quarter, compared to the consensus estimate of $464.81 million. During the same quarter in the previous year, the company posted $0.26 earnings per share. The business's quarterly revenue was up 13.4% compared to the same quarter last year. Equities analysts forecast that UiPath, Inc. will post 0.32 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on PATH. Barclays boosted their target price on UiPath from $16.00 to $18.00 and gave the stock an "equal weight" rating in a research report on Monday, January 12th. Canaccord Genuity Group dropped their price target on UiPath from $19.00 to $15.00 and set a "buy" rating on the stock in a research report on Thursday, March 12th. Mizuho dropped their price target on UiPath from $15.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, March 12th. UBS Group dropped their price target on UiPath from $17.00 to $13.00 and set a "neutral" rating on the stock in a research report on Thursday, March 12th. Finally, Wall Street Zen lowered UiPath from a "strong-buy" rating to a "buy" rating in a research report on Saturday, March 28th. Three investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, UiPath currently has a consensus rating of "Hold" and a consensus price target of $14.07.
Get Our Latest Analysis on UiPath
About UiPath
(
Free Report)
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization. Its platform's embedded AI, ML, and NLP capabilities improve decisioning and information processing; emulate human behavior allows organizations to address a myriad of use cases; emulate human behavior allows organizations to address a myriad of use cases; multi-tenant platform enterprise deployment with security and governance and Automation Cloud, which enables customers to begin automating without the need to provision infrastructure, install applications, or perform additional configurations; intuitive interface and low-code, drag-and-drop functionality; signed to enable people and automations to work together; and tracks, measures, and forecasts the performance of automations, enables customers to gain powerful insights and generate key performance indicators with actionable metric.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider UiPath, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UiPath wasn't on the list.
While UiPath currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.